ASCO GU 2022

Neoadjuvant therapy in UTUC: Good options for selected…

Role of PARPi in urothelial cancer

Follow-up data confirm OS benefit across subgroups

ADCs will be step-changing in urothelial cancers

Exciting data supports trimodality therapy

Mature data confirm efficacy of maintenance avelumab as…

Ongoing immunotherapy innovation for mCRPC

ADC shape the therapy landscape in urothelial cancer

HER2 ERBB2 – entering precision oncology

Patient selection for adjuvant Nivolumab (TPS vs. CPS)

Not practice changing, but hypothesis generating.

Patient selection for bladder preservation

IO escalation results in improved response in met. TCC.

Theranostics – Presence and future: Vision, PSMAfore,…

Enza beyond progression? Practice changing or not?

The future of genetic testing. Somatic vs. germline?…

Do we need testing? Which biomarkers are of relevance?

Addition of darolutamide improves OS in met.…

New therapies and molecular targets in prostate cancer

PSMA and FDG PET as biomarkers for response to LuPSMA

PSA response correlates with OS and benefits in QoL

Triplet-therapy as a novel treatment option

Should we use arbiraterone and niraparib as 1st line…

HRR testing: MAGNITUDE vs. PROpel

The importance of conducting HCRA

Subgroup analyses confirm the importance of oral daily…

Should we use arbiraterone and olaparib as 1st line…

Where do PROpel and Magnitude agree?

DARO in triplet therapy for CRPC

How to improve PSMA based radioligand therapy

Exciting new compound for mCRPC

PROpel & Magnitude: who wins the race?

PRESIDE indicates benefit of continuation ENZA + ADT

The need for biomarker panels in biopsy decision making

Is the dual hormone-backbone the future?

Is docetaxel still needed for hormone sensitive mCRPC?

Neoadjuvant IO+TKI Treatment: We need more data on…

Thoughts on first line treatment options following ASCO…

Adjuvant PD1 Therapy confirms significant benefit for…

Update in adjuvant therapy for kidney cancer

Data gap in 2nd line RCC: what’s new?

Neoadjuvant avelumab/axitinib - NeoAvAx

Update in neoadjuvant therapy for kidney cancer

Nivo montoherapy followed by Nivi-Ipi resuce

Frontline treatment of metastatic kidney cancer

CheckMate final OS Follow Up and health related QoL

Microbioma modification and checkpoint inhibition

Adjuvant Pembroluzimab update in kidney cancer